Activity of Novel Ceftibuten-Avibactam, Ceftazidime-Avibactam, and Comparators Against a Challenge Set of Enterobacterales From Outpatient Centers and Nursing Homes Across the United States (2022–2024)

Authors

• Aliaa Fouad, Hartford Hospital
• April M. Bobenchik, Penn State Health Milton S. Hershey Medical Center
• Robin Chamberland, Saint Louis University
• Andrew E. Clark, The University of Texas
• Holly K. Huse, Harbor-UCLA Medical Center
• Isabella W. Martin, Dartmouth Health
• A. Brian Mochon, University of Arizona
• Erik Munson, Marquette UniversityFollow
• Maroun M. Sfeir, University of Connecticut
• Monica Srodon, Eastern Connecticut Health Network
• Kimberly Taylor, American Health Associates Laboratory
• Yungchou Wang, Cape Regional Health System
• Lars F. Westblade, Weill Cornell Medicine
• David P. Nicolau, Hartford Hospital
• Tomefa E. Asempa, Hartford Hospital

Document Type

Article

Publication Date

5-2025

Publisher

American Society for Microbiology

Source Publication

Antimicrobial Agents and Chemotherapy

Source ISSN

0066-4804

Original Item ID

DOI: 10.1128/aac.01867-24

Abstract

Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.

Comments

Published version. Antimicrobial Agents and Chemotherapy, Vol. 69, No. 5 (May 2025): e0186724. DOI. © 2025 The Authors, published by American Society for Microbiology. Used with permission.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Fouad, Aliaa; Bobenchik, April M.; Chamberland, Robin; Clark, Andrew E.; Huse, Holly K.; Martin, Isabella W.; Mochon, A. Brian; Munson, Erik; Sfeir, Maroun M.; Srodon, Monica; Taylor, Kimberly; Wang, Yungchou; Westblade, Lars F.; Nicolau, David P.; and Asempa, Tomefa E., "Activity of Novel Ceftibuten-Avibactam, Ceftazidime-Avibactam, and Comparators Against a Challenge Set of Enterobacterales From Outpatient Centers and Nursing Homes Across the United States (2022–2024)" (2025). Clinical Lab Sciences Faculty Research and Publications. 82.
https://epublications.marquette.edu/clinical_lab_fac/82